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Development of immunoprotection against visceral leishmaniasis (VL) focused on the 
identification of antigens capable of inducing a Th1 immune response. Alternatively, 
antigens targeting the CD8 and T-regulatory responses are also relevant in VL patho-
genesis and worthy of being included in a preventive human vaccine. We assessed in 
active and cured patients and VL asymptomatic subjects the clinical signs and cytokine 
responses to the Leishmania donovani nucleoside hydrolase NH36 antigen and its 
N-(F1), central (F2) and C-terminal (F3) domains. As markers of VL resistance, the F2 
induced the highest levels of IFN-γ, IL-1β, and TNF-α and, together with F1, the stron-
gest secretion of IL-17, IL-6, and IL-10 in DTH+ and cured subjects. F2 also promoted 
the highest frequencies of CD3+CD4+IL-2+TNF-α−IFN-γ−, CD3+CD4+IL-2+TNF-α+IFN-γ−, 
CD3+CD4+IL-2+TNF-α−IFN-γ+, and CD3+CD4+IL-2+TNF-α+IFN-γ+ T cells in cured and 
asymptomatic subjects. Consistent with this, the IFN-γ increase was correlated with 
decreased spleen (R = −0.428, P = 0.05) and liver sizes (R = −0.428, P = 0.05) and with 
increased hematocrit counts (R = 0.532, P = 0.015) in response to F1 domain, and with 
increased hematocrit (R = 0.512, P 0.02) and hemoglobin counts (R = 0.434, P = 0.05) 
in response to F2. Additionally, IL-17 increases were associated with decreased spleen 
and liver sizes in response to F1 (R = −0.595, P = 0.005) and F2 (R = −0.462, P = 0.04). 
Conversely, F1 and F3 increased the CD3+CD8+IL-2+TNF-α−IFN-γ−, CD3+CD8+IL-2+TNF-
α+IFN-γ−, and CD3+CD8+IL-2+TNF-α+IFN-γ+ T cell frequencies of VL patients correlated 
with increased spleen and liver sizes and decreased hemoglobin and hematocrit values. 
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inTrODUcTiOn
Visceral leishmaniasis (VL) is a severe chronic vector-borne 
protozoan disease. Approximately 400,000 new cases of VL 
and 30,000 deaths are reported annually (1), and the worldwide 
incidence is increasing due to co-infection with HIV and the 
expanded geographical range of the insect vector subsequent to 
global warming (2). The disease is caused by Leishmania donovani 
in India, Asia, and East Africa; by Leishmania infantum chagasi in 
America; and by Leishmania infantum in the Middle East, Central 
Asia, China, and the Mediterranean (2). Bangladesh, India, Nepal, 
Sudan, Ethiopia, and Brazil concentrate 90% of the VL worldwide 
incidence (2). Clinical findings of VL range from asymptomatic 
cases with self-resolving infection and an anti-Leishmania 
integral immune response to severe cases characterized by 
intermittent fever, malaise, weight loss, cachexia, hepatomegaly, 
splenomegaly, hypergammaglobulinemia, anemia, leukopenia, 
thrombocytopenia, strong suppression of the CD4+ T-cell 
immune response, and death, if untreated (3). Chemotherapy is 
highly toxic, and the long-term use of this treatment can select for 
resistant parasites (4).
Asymptomatic subjects and cured individuals from endemic 
areas have an effective CD4+-Th1 immune response against 
Leishmania and are resistant to the disease on the basis of a posi-
tive Leishmania-specific delayed-type hypersensitivity (DTH+) 
skin test response (4–6). Delayed-type of hypersensitivity 
response (DTH) is mediated by the Th1 subset of CD4+ cells (7) 
and lost during sever VL (4–6). Identification of the antigens and 
HLA-restricted epitopes correlating with the natural resistance 
and cure of VL, and of the epitopes recognized during the severe 
disease is necessary to guide the development of a rational vac-
cine and to understand the precise immune mechanisms required 
for controlling parasite growth (4, 5).
Visceral leishmaniasis is associated with polarization to a Th2 
immune response with increased production of IL-10 and TGF-β 
(8) and depletion of the Th1 cytokines IFN-γ, TNF-α, IL-2, and 
IL-12 produced by PBMCs in response to leishmanial lysates (4, 
8, 9). The development of successful protection or resistance to 
VL requires, the generation of potent and durable Th1 parasite-
specific memory responses, characterized by the production 
of IFN-γ, IL-2, and TNF-α by multifunctional CD4+ T cells (4, 
10–13). Additionally, the assessment of the balance between 
immunoregulatory mechanisms, including pro-inflammatory 
IFN-γ and TNF-α, and the secretion of IL-17 and the regulatory 
cytokine IL-10 (4, 8) is required. Furthermore, CD8 T cells were 
also recently described, as contributing to the cure or pathology 
of VL (8, 14).
Many Leishmania antigens have been tried as potential vaccine 
candidates with varied immune responses and diverse species-
specific protection (14–16). Leishmune® is the first licensed 
second-generation vaccine against VL. It is composed of the 
FML glycoproteic antigen of L. donovani and saponin (17–19). Its 
recent use has already resulted in the reduction of the incidence of 
dog and human VL in Brazil (20). The nucleoside hydrolase of L. 
donovani (NH36) is the Leishmune® main antigen and one of the 
promising candidates for vaccination against VL (17). Notably, 
NH36 is a vital enzyme of Leishmania that releases purines or 
pyrimidines from foreign DNA to be used in the synthesis of 
parasite DNA. Because it is absent from mammalian cells, it is a 
good target for differential chemotherapy (21, 22).
Vaccination with recombinant NH36 protein or DNA, pro-
tected mice from L. donovani (23), Leishmania major (24), L. 
infantum chagasi (25, 26), L. mexicana (25), and Leishmania ama-
zonensis (12, 13) infections and also protected dogs infected with 
L. infantum chagasi through a Th1 immune response mediated 
by IFN-γ-producing CD4+ T cells (27). After vaccination with 
the recombinant NH36 in the mouse model, we described the 
achievement of 88% prophylactic protection (26) and 91% cure of 
VL (28), and 65–81% cure of cutaneous leishmaniasis (CL) (13).
NH36 is a strong phylogenetic marker of the Leishmania genus 
(11, 13, 29) that mediates high levels of vaccine cross-protection. 
In fact, the amino acid sequence of L. donovani NH36 shows high 
identity with the NH sequences of L. major (95–96%) (11, 30), L. 
mexicana (93%), L. infantum chagasi (99%), L. infantum (99%), 
Leishmania tropica (97%), Leishmania braziliensis (84%) (31), 
and L. amazonensis (93%) (12).
Our objective was to determine the major epitopes that 
contribute to protective responses, and this was done directly 
from the whole NH36 molecule. In fact, the in silico prediction 
disclosed the epitopes of NH36 for mice (12, 26) and human his-
tocompatibility complex molecules (this investigation). However, 
although this information would allow the direct design of a 
synthetic epitope vaccine, the results of the immunological 
assays in vivo not always confirm the in  silico predictions (32), 
and the synthetic epitopes alone are not enough immunogenic 
to be used as vaccine candidate antigens (14). Our strategy then 
Therefore, cure and acquired resistance to VL correlate with the CD4+-Th1 and Th-17 
T-cell responses to F2 and F1 domains. Clinical VL outcomes, by contrast, correlate 
with CD8+ T-cell responses against F3 and F1, potentially involved in control of the early 
infection. The in silico-predicted NH36 epitopes are conserved and bind to many HL-DR 
and HLA and B allotypes. No human vaccine against Leishmania is available thus far. In 
this investigation, we identified the NH36 domains and epitopes that induce CD4+ and 
CD8+ T cell responses, which could be used to potentiate a human universal T-epitope 
vaccine against leishmaniasis.
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was to identify through immunological assays the presence of the 
important epitopes in shorter sequences of the NH36 antigen that 
would be, therefore, more potent than the whole cognate protein 
and more immunogenic than the isolated epitopes.
Knowing that NH36 was a vital parasite enzyme (33, 34), 
a conserved molecule of the Leishmania genus (29), and an 
important antigen (35), we designed three subunit vaccines that 
would cover the whole sequence of NH36. Since NH36 has 314 
amino acids, we subcloned and obtained its N-terminal (F1) 
domain (amino acids 1–103), the central (F2) domain (amino 
acids 104–198), and the C-terminal (F3) domain (amino acids 
199–314) (26). We first vaccinated mice with NH36 and used 
these domains to stimulate the splenocyte secretion of IFN-γ and 
TNF-α (36). Furthermore, we vaccinated mice with each one of 
the three domains and studied the cytokine secretion and intracel-
lular staining in response to NH36, the DTH, and the reduction 
of parasite load after infection with L. infantum chagasi (26). In 
both studies, F1 and F3 domains induced the strongest immune 
response (26, 36). However, mouse protection against L. infantum 
chagasi challenge was mediated by a CD4+ Th1 response directed 
only against F3 and was higher (88%) than that generated by the 
NH36 protein (68%) (26). The increases in DTH and in ratios of 
TNF-α/IL-10 CD4+-producing cells were the strong correlates of 
this protection, which was confirmed by in vivo depletion with 
monoclonal antibodies (26). In agreement, the in  silico predic-
tion identified three MHC class II-restricted epitopes in the F3 
domain (26). On the other hand, prevention (12) and cure (13) of 
L. amazonensis infection in mice were determined also by a CD4+ 
T-cell-driven response to F3 but with an additional CD8+ T-cell 
response directed to the F1 domain. Coincidentally, one highly 
scored epitope for MHC class I-restricted molecules was detected 
in the sequence of F1 (12, 26). In the meantime, the predictions 
of one MHC class II- and two MHC class I-restricted epitopes 
in the F2 domain were not confirmed by any immunologic or 
parasitological assay developed in the mice models of VL or CL 
(12, 13, 26). Our results then confirmed that both, the in silico 
predictions and the in vivo immunological assays, are needed to 
improve the definition of a T-cell epitope vaccine (32).
To this point, however, the NH36 epitopes recognized by the 
human major histocompatibility class I and II complexes (HLAs) 
were not yet described. In this investigation, we aimed to identify 
the main domains and epitopes of NH36 to be included in a 
future vaccine against human VL. For that purpose, we evaluated 
the clinical outcomes of VL patients, cured subjects, and asymp-
tomatic individuals of a Brazilian endemic area and assessed their 
correlations with cytokine expression, and with the induction of 
CD3+CD4+ and CD3+CD8+ multifunctional T cells, in response 
to the defined domains of NH36. We used these correlations 
as tools for identification of the domains of NH36 responsible 
for the cellular immune responses generated during resistance 
and progression of the disease. We were able to demonstrate the 
generation of Th1 and Th17 cells and regulatory cytokines, as well 
as a CD3+CD4+ Th1 multifunctional T-cell response, in cured and 
asymptomatic subjects. We additionally disclosed the generation 
of a CD3+CD8+ multifunctional T-cell response in VL patients. 
Finally, we identified the most immunodominant epitopes of L. 
donovani NH36 for the generation of CD4 and CD8 T cell immune 
responses in individuals infected with L. infantum chagasi. A 
rationale combination of the domains or epitopes that enhance 
both arms of T-cell immunity will contribute to the development 
of a universal protective or therapeutic vaccine against human VL 
and to the understanding of VL pathology.
MaTerials anD MeThODs
ethics
The protocols were performed according to the guidelines 
and regulations of the Brazilian National Council of Health 
resolution 196/96 (CAAE 0162.0.107.000-09). The protocols were 
performed according to the guidelines and regulations of the 
Brazilian National Council of Health resolution 196/96 (CAAE 
0162.0.107.000-09) and were approved by the Research Ethics 
Committee of the Universidade Federal de Sergipe. The objec-
tives of the study were explained to all invited participants who 
gave written informed consent in accordance to the Declaration 
of Helsinki. Participants were explained about the low risks of the 
procedures. Only small samples of venous blood were collected 
from them, and no invasive procedure was performed.
Patients
This study was performed with patients who were admitted to 
the UFS University Hospital, SE, Brazil, between March 2013 and 
March 2015. They were clinically diagnosed with VL based on 
fever, weight loss, anemia, spleen and liver enlargement, pancyto-
penia, hypergammaglobulinemy, positive culture in NNN media 
(Sigma-Aldrich), and positive serum reactivity to the rK39 antigen 
(KalazarDetect® Rapid Test, INBIOS International Inc., Seattle, 
WA, USA). Pregnant women, patients receiving immunosup-
pressive treatments, and those with diabetes or HIV or HTLV-1 
co-infections were excluded. Cure was monitored 180 days after 
therapy with Glucantime®. Household contacts or patient relatives 
with no signs of disease were recruited and skin-tested for DTH 
with Leishmania promastigote lysate kindly provided by Centro de 
Produção e Pesquisa de Imunobiológicos (CPPI, Paraná, Brazil). 
Indurations of diameters ≥5 mm, detectable at 48 h after antigen 
injection, were considered positive. Hematological, hematocrit, 
and hemoglobin evaluation of patients and DTH+ subjects was 
performed. Increases in the spleen and liver sizes were measured 
in centimeters, below the ribs’ lower edge. Healthy subjects from 
the endemic area were included as negative controls. A total of 67 
individuals were included in this study: 16 healthy controls, 14 
patients with active VL, 17 cured patients, and 20 asymptomatic 
DTH+ subjects. The group of untreated patients was increased to 
41 individuals in order to establish the correlations between the 
increases of spleen and liver sizes.
recombinant antigens and epitopes
NH36 [EMBL, Genbank, and DDJB databases, access number 
AY007193 GENBANK (AY007193 and AAG02281.1 access codes) 
and in SWISS-PROT (Q8WQX2 UNi-Prot access code)] and its 
N-terminal (F1, amino acids 1–103), central (F2, amino acids 
104–198), and C-terminal (F3, amino acids 199–314) domains 
were cloned in E. coli (26), expressed, and purified as modified 
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from the methods of Rodrigues et al. (37) and Saini et al. (38). 
Briefly, protein expression was induced in bacterial suspensions 
with 1 mM IPTG, for 4 h at 37°C. The cells were sonicated, and 
the insoluble pellets were washed twice with 10 mM Tris–HCl 
pH 8.0 and 0.5% CHAPS and further treated for 2  h at 37°C, 
under agitation, with a solubilization buffer composed of 20 mM 
Tris–HCl pH 8.0, 500  mM NaCl, 10% glycerol, and 8  M urea. 
Then, the suspension was homogenized by successive passages 
through 20-ml syringes with 1.2 mm × 40 mm needles followed 
by centrifugation, for 30 min at 14,000 rpm. The supernatant was 
loaded on a Ni-NTA chromatography column previously equili-
brated with solubilization buffer. After sample application, the 
column was washed with three volumes of solubilization buffer 
containing 20  mM imidazole. Next, the column was washed 
with three volumes of the same buffer containing 5 mM reduced 
glutathione, 0.1% Triton X-100, and each one of the decreasing 
concentrations of a urea gradient (6–1 M), and buffer with no 
urea added for refolding. Elution of the proteins was achieved 
using 250  mM imidazole in refolding buffer without urea and 
confirmed by protein assay and 15% SDS-PAGE. The proteins 
were finally dialyzed against 50  mM Tris–HCl, pH 8, 50  mM 
NaCl, 50% glycerol, and 0.1 mM DTT and the absence of LPS was 
confirmed using the LAL QCL-1000 kit (Lonza). The purification 
process yielded 1  mg protein antigen per liter of bacterial cul-
ture. The homology between the sequence of L. donovani NH36 
(GenBank: AAG02281.1) and Leishmania infantum chagasi NH 
(Lch-NH) (GenBank: AAS48353.1) was determined using NIH-
NCBI Standard Protein BLAST software. A molecular model 
was obtained by homology modeling using the Modeller 9.10 
software and data for the nucleoside hydrolase from a L. major 
template (RCSB PDB code: 1EZR; crystal structure of nucleoside 
hydrolase of L. major) (39).
For control purposes, in order to further demonstrate that 
NH36 is a component of SLA, we also assayed if sera of mice 
vaccinated with three doses of 100 μg of either NH36, F1, F2, or 
F3 recombinant antigens formulated with 100 μg saponin, with a 
weekly interval, recognized the SLA of L. infantum chagasi (2 μg/
well) in a standard ELISA assay using peroxidase-conjugated 
protein A (26).
HLA-DR-binding CD4 epitopes were mapped with the 
TEPITOPE program. CD8 epitopes were identified using 
SYFPEITHI software. The predicted epitopes were synthetized 
by GenScript (NJ, USA). The analysis of the identity of the 
epitopes in the different leishmanial species was performed using 
the sequences of nucleoside hydrolase of Leishmania species of 
PubMed Protein Databank and the sequence of L. amazonensis 
NH A34480 (12).
cytokine secretion
PBMCs were obtained from heparinized vein blood using a 
standard Ficoll-Hypaque procedure, washed twice with RPMI 
1640 and counted microscopically with Trypan Blue. The cells 
were plated (2 × 105/well) and stimulated with 10 μg/ml of NH36, 
F1, F2, and F3, stationary phase L. donovani promastigote lysate 
or with no addition for 72 h at 30°C and 5% CO2. The secretion of 
IFN-γ, TNF-α, IL-1β, IL-4, IL-6, IL-12p70, IL-10, and IL-17 into 
the supernatants was evaluated with a Multiplex® MAP-Luminex 
MAP® kit and analyzed using Milliplex Analist 5.1 software 
(Merck Millipore, Billerica, MA, USA), according to the manu-
facturer’s instructions. The sensitivity of the assay was established 
with a range of 8–15,000  pg/ml recombinant cytokines. We 
further assessed the IFN-γ secretion by PBMC of asymptomatic 
subjects in response to the synthetic predicted epitopes using the 
Invitrogen™ NOVEX™ IFN-γ Human Ultrasensitive Magnetic 
Bead kit (USA).
intracellular cytokine staining
PBMCs (2 × 106/well) were in vitro cultured in 96-well/plates with 
10 μg/ml of NH36, F1, F2, and F3, stationary phase L. donovani 
promastigote lysate or with no addition, for 6 h, followed by the 
addition of Brefeldin A (GolgiPlus, BD Biosciences, Franklin 
Lakes, NJ, USA), and further incubation for 12 h. The plates were 
centrifuged at 1,430 rpm for 5 min at 4°C, washed with PBS, and 
blocked with 2% fetal goat and 2% fetal bovine calf sera. The 
cells were further stained for surface markers with V500 mouse 
anti-human CD3 clone UCHT1 (RUO), FITC mouse anti-human 
CD4 clone RPA-T4 (RUO), and PE-Cy5 mouse anti-human CD8 
clone RPA-T8 (RUO) monoclonal antibodies (BD Biosciences 
Pharmingen, San Diego, CA, USA), washed with PBS, and fixed 
and permeabilized with the Cytofix/Cytoperm mixture (BD 
Biosciences, Pharmingen, San Diego, CA, USA) for 20 min. The 
cells were then stained for the intracellular expression of cytokines 
with anti-IL-2-BV421 (clone 5344.111), anti-TNF-α-PE (clone 
Mab 11), and anti-IFN-γ-PE-Cy7 (clone B27) antibodies (BD 
Biosciences Pharmingen), washed with Perm Wash buffer (BD 
Biosciences Pharmingen), and resuspended in PBS. A minimum 
of 30,000 events were acquired on a BD FACSCanto II™ flow 
cytometer and analyzed using FlowJo software (Tree Star Inc., 
Ashland, OR, USA). All T cell frequencies were recorded after 
background subtraction of cells incubated without antigen.
For multiparameter cytometry analysis, the gated single-cell 
lymphocyte population was additionally gated for CD3 expression 
and subsequently for CD4 or CD8 expression. Production of each 
cytokine (IL-2, TNF-α, and IFN-γ) were analyzed individually 
inside CD3+CD4+ or CD3+CD8+ T cells gate. Boolean gating was 
used to generate combinations of cytokine expression and types 
of lymphocytes in order to identify lymphocytes expressing one 
cytokine or any combination of two cytokines or three cytokines 
(Figure S5 in Supplementary Material).
statistical analysis
Kruskal–Wallis and Mann–Whitney tests were used for means 
comparison, and Spearman’s two-tailed correlation test was used 
for correlation analysis using GraphPad Prism 6.03 software. All 
experiments were performed at least twice, and the indicated 
error bars are based on the SEM.
resUlTs
clinical Outcomes of Vl Patients
Clinical examination and laboratory exams of patients before 
treatment revealed the typical sign of VL: hepatomegaly, sple-
nomegaly, leukopenia, neutropenia, eosinopenia, lymphopenia, 
TaBle 1 | comparison of clinical outcomes.
clinical outcomes Vl patients cured patients asymptomatic 
DTh+ subjects
Mean (se) Mean (se) P 
value
Mean (se) P 
value
Spleen increase 
in cm
1.7 (0.6) 0 (0) 0.002 0 (0) 0.001
Liver increase in cm 0.8 (0.3) 0 (0) 0.045 0 (0) 0.027
Leukocytes per mm3 2,384 (477) 6,047 (1,234) 0.018 7,556 (674) 0.001
Neutrophils per mm3 712 (285) 3,407 (780) 0.010 4,941 (701) 0.001
Eosinophils per mm3 18.5 (7.7) 93.9 (52) 0.183 337.3 (66) 0.001
Lymphocytes per 
mm3
1,094 (244) 2,068 (368) 0.045 2,724 (454) 0.008
Monocytes per mm3 297 (72.3) 433 (32.4) 0.097 543 (59) 0.019
Hematocrit (%) 28.4 (2.6) 40.9 (2.3) 0.006 41.4 (1.5) 0.004
Hemoglobin (gr/dl) 8.9 (0.8) 13.7 (0.8) 0.002 13 (0.5) 0.002
Platelets per 10−3/μl 123.4 (25.9) 169.8 (14.4) 0.184 262.1 (14.2) 0.001
P values express the significance of the differences to the clinical outcomes of visceral 
leishmaniasis (VL) patients before treatment. Means + SE. N = 9 VL patients before 
treatment, N = 8 cured VL patients, and N = 10 asymptomatic DTH+ subjects.
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monocytopenia, thrombocytopenia, and decreased hematocrit 
and hemoglobin levels (Table 1). Conversely and as expected for 
their natural resistance status to infection, all outcomes remained 
at normal levels in DTH+ asymptomatic subjects and in cured 
subjects, except for eosinophils, monocytes, and platelets.
expression and Purification of nh36 and 
its Domains
Each bacterial clone codifying for the sequences of the recom-
binant NH36 and its F1, F2, and F3 domains was cultured into 
2  l of bacterial culture media and induced for expression with 
IPTG. Conditions of expression and purification of the antigens 
are summarized in Figure S1A in Supplementary Material. The 
yield of each expression batch was 4.62 mg for NH36, 5.00 mg for 
F1, 3.5 mg for F2, and 3.75 mg for F3. The antigens were main-
tained at −80°C until use. A standardization study proved that 
the protein concentration was preserved at −80°C until at least 
24 months after purification. SDS-PAGE analysis disclosed that 
the expressed proteins showed their expected molecular weights: 
34,238.6 Da for NH36, 10,845.5 Da for F1, 10,327.9 Da for F2, 
and 13,101.1 Da for F3 (Figure S1B in Supplementary Material).
cytokine secretion in response to nh36 
Domains
We investigated which NH36 domains target the cellular immune 
response. The secretion of most cytokines was enhanced in cured 
and DTH+ subjects above the levels detected in patients before 
treatment, except for IL12p70 (Figure  1). Additionally, the 
secretion of IFN-γ, IL-17, and IL-10 was lower in patients before 
treatment than in healthy controls of endemic areas.
We observed discrete, but significant, differences between the 
immunogenicity of NH36 domains. The F2 peptide alone induced 
the highest levels of IFN-γ, IL-1β, and TNF-α. Furthermore, F1 
and F2 domains together promoted the strongest secretion of 
IL-17, IL-6, and IL-10 in DTH+ and cured subjects (Figure 1). 
Noteworthy, SLA induced lower levels of IL-1β and IL-10 than F1 
and F2 domains (Figure 1). F2 was also the predominant domain 
that secreted higher levels of IL12p70 than SLA, but in patients 
before treatment. Conversely, IL-4 secretion was promoted only 
by SLA in cured and DTH+ individuals (Figure 1). We also show 
that serum antibodies of mice vaccinated with NH36, F1, F2, or 
F3 domains and saponin recognize the SLA antigen of L. infantum 
chagasi in an ELISA assay, indicating that NH36 is an antigenic 
component of SLA (Figure S2 in Supplementary Material).
We further investigated if this Th1 response correlates with the 
natural resistance to VL. In fact, the IFN-γ increase in response to 
F1, and the secretion of IL-17 in response to F1 and F2, strongly 
correlates with the decreases of spleen and liver sizes, which are 
signals of resistance to Leishmania infection (Table 2; Figure S3 
in Supplementary Material). The increases in liver and spleen 
sizes are highly correlated (R = 0.796, P < 0.0001) (Figure S4 in 
Supplementary Material).
Furthermore, the increase of IFN-γ secretion in response to F1 
and F2 domains correlates with the increase of hematocrit and, in 
response to the F2 peptide, also correlates with the increment in 
Hg concentration (Table 2; Figure S4 in Supplementary Material). 
Likewise, IL-17 secretion in response to F1 correlated with the 
increase in monocyte counts and Hg concentration (Table  2; 
Figure S4 in Supplementary Material). Increases in hematocrit, 
hemoglobin concentration and monocyte counts are markers of 
resistance and cure of VL.
We found also significant correlations between the IL-17 and 
IL-6 secretions promoted by NH36 and the decreases in spleen 
and liver weights (Table  2). Also, the increases in monocyte 
counts and IL-6 secretion in response to NH36 were correlated.
intracellular expression of cytokines in 
response to nh36 Domains
We further investigated the cellular immune response to NH36 
domains by multiparameter cytometry analysis. The strategy that 
we used for the analysis of multifunctional T cell response using 
multiparameter flow cytometry is summarized in Figure S5 in 
Supplementary Material. The total frequencies of CD3+CD4+ T 
cells were reduced in patients with active VL (P < 0.031), com-
pared to DTH+ subjects (Figure 2A). This is in agreement to the 
lower IFN-γ secretion found in VL patients (Figure 1).
In DTH+ subjects, the NH36 domains induced higher 
frequencies of CD4 T cells secreting one, two (except for 
CD3+CD4+IL-2−TNF-α+IFN-γ+), and three cytokines compared 
to those in cured individuals (P < 0.031) or controls (P < 0.031), 
suggesting the involvement of CD4 epitopes in natural resistance 
to VL (Figure 2A). Confirming the results of cytokine expres-
sion, F2 was the predominant inducer of the CD4+ Th1 response 
and alone induced the highest frequencies of CD3+CD4+IL-
2+TNF-α+IFN-γ− and CD3+CD4+IL-2+TNF-α−IFN-γ+ T cells. 
Furthermore, together with NH36, F2 induced the highest single 
(CD3+CD4+IL-2+TNF-α−IFN-γ−) and total (CD3+CD4+IL-2+) 
frequencies of IL-2+ and of multifunctional CD4 T cells 
(CD3+CD4+IL-2+TNF-α+IFN-γ+) (Figure  2A), and the lowest 
FigUre 1 | cytokine release in the supernatants of PBMcs after in vitro incubation with nh36, F1, F2, or F3. PBMCs were isolated from venous blood 
and incubated in vitro with 10 μg/ml recombinant NH36, F1, F2, and F3 antigens, with Leishmania donovani stationary phase lysate, or with no addition, for 72 h. 
Cytokine secretion in supernatants was measured with a Multiplex® MAP-Luminex assay. Asterisks and horizontal lines indicate significant differences between 
groups. • indicates differences in the same group of patients induced by other antigens. The means + SE are shown. N = 6 in the normal healthy control group; 
N = 7 in the active VL group; N = 9 in the cured group; and N = 10 in the asymptomatic DTH+ group.
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proportions of CD3+CD4+IL-2−TNF-α−IFN-γ+ T cells, in DTH+ 
and cured subjects.
Additionally, single producers of IL-2 (CD3+CD4+IL-2+TNF-
α−IFN-γ−) represented the predominant fraction of the CD4 
response in cured patients, while single producers of TNF-α 
(CD3+CD4+IL-2−TNF-α+IFN-γ−) were the major fraction in 
DTH+ subjects (Figure 2B). The F2 domain generated the most 
potent response, and this was confirmed by the finding that it 
stimulated the highest percentages of CD3+CD4+IL-2+TNF-
α−IFN-γ− single producers (55 and 50%), CD3+CD4+IL-2+TNF-
α+IFN-γ− (23 and 5%), CD3+CD4+IL-2+TNF-α−IFN-γ+ (3 and 
3%), and CD3+CD4+IL-2+TNF-α+IFN-γ+ multifunctional T cells 
(0.89 and 47%) in cured and DTH+ individuals, respectively. These 
results confirm that this domain generates the most advanced 
TaBle 2 | correlation between clinical status, cytokine secretion and frequencies of cD4+ and cD8+ lymphocytes secreting one, two, or three 
cytokines, in response to nh36 domains.
cytokines nh36 F1 F2 F3
R value P value R value P value R value P value R value P value
IFN-γ Spleen size −0.428 0.050
Liver size −0.428 0.050
Hematocrit 0.532 0.015 0.512 0.020
Hemoglobin 0.434 0.050
IL-17 Spleen size −0.546 0.012 −0.595 0.005 −0.462 0.040
Liver size −0.546 0.012 −0.595 0.005 −0.462 0.040
Monocytes 0.539 0.014 0.580 0.007
Hemoglobin 0.466 0.038
IL-6 Spleen size −0.464 0.039
Liver size −0.464 0.039
CD3+CD4+IL-2−TNF-α+IFN-γ− Neutrophils 0.452 0.027 0.437 0.003
CD3+CD4+IL-2−TNF-α−IFN-γ+ Monocytes 0.458 0.024
Hematocrit −0.432 0.035
Neutrophils 0.432 0.035
CD3+CD4+IL-2+TNF-α−IFN-γ+ Platelets 0.476 0.019 0.454 0.026
CD3+CD4+IL-2+TNF-α+IFN-γ+ Leukocytes 0.405 0.050
CD3+CD8+IL-2+TNF-α−IFN-γ− Spleen size 0.424 0.034
Hemoglobin −0.534 0.006
Hematocrit −0.526 0.007
CD3+CD8+IL-2−TNF-α−IFN-γ+ Eosinophils 0.412 0.045
Monocytes 0.672 0.001 0.766 0.001 0.406 0.049 0.480 0.017
CD3+CD8+IL-2+TNF-α−IFN-γ+ Liver size 0.557 0.005
CD3+CD8+IL-2−TNF-α+IFN-γ+ Monocytes 0.566 0.004 0.599 0.002
CD3+CD8+IL-2+TNF-α+IFN-γ+ Spleen size 0.445 0.029 0.403 0.051
Liver size 0.603 0.002 0.621 0.001
Leukocytes 0.421 0.040
Neutrophils 0.412 0.046
Non-parametric Spearman two-tailed correlation analysis between the outcomes of clinical variables and cytokines secreted in vitro, or frequencies of CD3+CD4+ and CD3+CD8+ T 
cells secreting 1+, 2+, and 3+ cytokines in vitro, in response to incubation with NH36, F1, F2, or F3 antigens.
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stage of differentiation of the CD4 response (Figures  2A,B). 
F1 and F3, on the other hand, induced the highest frequencies 
of CD3+CD4+IL-2−TNF-α+IFN-γ− and CD3+CD4+IL-2−TNF-
α−IFN-γ+ single producers (Figure 2B).
We found interesting correlations between the clinical 
outcomes of VL and T cell immunity to NH36 antigens. As 
correlates of VL resistance or cure, the increases of frequencies 
of CD3+CD4+IL-2−TNF-α+IFN-γ−, CD3+CD4+IL-2−TNF-
α−IFN-γ+, and multifunctional CD3+CD4+IL-2+TNF-α+IFN-γ+ 
T cells induced by F1 were significantly associated with the 
increases in neutrophil, monocyte, and leukocyte counts, respec-
tively (Table  2). Additionally, the increases in CD3+CD4+IL-
2−TNF-α−IFN-γ+ frequencies generated by F2 correlated with 
the neutrophil counts, and the increase in CD3+CD4+IL-2+TNF-
α−IFN-γ+ correlated with the platelets counts. In contrast and as 
a marker of susceptibility to VL, the F3 induced CD3+CD4+IL-
2−TNF-α−IFN-γ+ T cell frequency was inversely correlated with 
the hematocrit values (Table 2).
Additionally, the analysis of the cytotoxic response disclosed 
that the total frequency of CD3+CD8+ T cells (Figure  3A) 
was lower in patients and higher in DTH+ and cured subjects. 
However, unlike the predominant enhancement of CD3+CD4+ 
T-cell frequencies, observed in DTH+ individuals (Figure 2A), 
the frequencies of CD3+CD8+ T cells producing cytokines, 
except for the single producers of TNF-α (CD3+CD8+IL-2−TNF-
α+IFN-γ−) and IFN-γ (CD3+CD8+IL-2−TNF-α−IFN-γ+), were 
higher in patients with active VL (P < 0.028–0.050) (Figure 3A), 
suggesting the importance of CD8 epitopes in the development 
of the disease.
F1 and F3 induced the highest single and total frequencies 
of CD8 T cells secreting IL-2 (CD3+CD8+IL-2+TNF-α−IFN-γ− 
and CD3+CD8+IL-2+) and of multifunctional CD8 T cells 
(CD3+CD8+IL-2+TNF-α+IFN-γ+), and F3 alone induced the 
highest proportions of CD3+CD8+IL-2+TNF-α+IFN-γ− and 
CD3+CD8+IL-2+TNF-α−IFN-γ+ T cells (Figure  3A). F2 
promoted low frequencies of CD3+CD8+IL-2+TNF-α−IFN-γ− 
cells in DTH+ subjects, NH36 induced higher frequencies of 
CD3+CD8+IL-2−TNF-α+IFN-γ− T cells in cured patients, while 
the CD3+CD8+IL-2−TNF-α−IFN-γ+ T-cell frequencies were 
enhanced in DTH+ individuals (P <  0.0286), regardless of the 
antigen used (Figure 3A).
Furthermore, in patients before treatment, F1 and F3 induced 
the highest percentages of CD3+CD8+IL-2+TNF-α+IFN-γ+ multi-
functional cells (3.17 and 0.84%, respectively), while F1 promoted 
FigUre 2 | continued
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FigUre 2 | continued 
Distinct quality of cD4 T cell response induced by nh36 or its domains. PBMCs were incubated in vitro with 10 μg/ml recombinant NH36, F1, F2, and F3 
antigens or with no antigenic stimulation for 6 h and further treated with brefeldin A for additional 12 h. Then, the cells were stained for surface CD3 and CD4 
markers, fixed, permeabilized, and stained for the intracellular expression of IL-2, TNF-α, and IFN-γ. Multiparametric flow cytometry was used to determine (a) the 
frequencies of CD3+CD4+ lymphocytes and of CD3+CD4+ lymphocytes single producers of each one of the three cytokines (CD3+CD4+IL-2+TNF-α–IFN-γ–, 
CD3+CD4+IL-2–TNF-α+IFN-γ–, and CD3+CD4+IL-2–TNF-α–IFN-γ+), double producers (CD3+CD4+IL-2+TNF-α+IFN-γ–, CD3+CD4+IL-2–TNF-α+IFN-γ+, and CD3+CD4+IL-
2+TNF-α–IFN-γ+), and multifunctional CD3+CD4+ T cells (CD3+CD4+IL-2+TNF-α+IFN-γ+); as well as the total frequencies of CD3+CD4+ cells producing IL-2 
(CD3+CD4+IL2+) and (B) the fraction of the total CD3+CD4+ T cell response comprising cells expressing all three cytokines, any two cytokines, or any one cytokine in 
healthy individuals (control N = 10), active visceral leishmaniasis (VL) patients before therapy (BT N = 7), cured VL patients after therapy (AT N = 9), and in 
asymptomatic DTH+ individuals (DTH+ N = 10). The frequencies of each cytokine expressing phenotype were recorded after background subtraction of cells 
incubated without antigen. Results in panel (a) are expressed as means + SE. Asterisks and horizontal lines indicate significant differences from all other groups.
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the highest fraction of the CD3+CD8+IL-2+TNF-α−IFN-γ− T cells 
(68%) and F3, the highest contribution of CD3+CD8+IL-2+TNF-
α+IFN-γ− T cells (74%) (Figure 3B). Cured and DTH+ subjects 
showed an enhanced fraction of CD3+CD8+IL-2−TNF-α+IFN-γ− 
secreting lymphocytes. A multifunctional CD3+CD8+ T cell 
contribution was also found in cured patients, in response to F2 
and in DTH+ subjects in response to F2 and F3. Interestingly, F1 
and F3 promoted the highest frequencies of CD8 T cells secreting 
only IFN-γ (CD3+CD8+IL-2−TNF-α−IFN-γ+), in DTH+ subjects 
(Figure 3B).
In addition, we analyzed if the cytotoxic response was cor-
related with the clinical outcomes (Table 2). As a marker of the 
advancement of the disease, F1 induced increased frequencies of 
CD3+CD8+IL-2+TNF-α−IFN-γ− T cells, which were correlated 
with increased spleen sizes and decreased hemoglobin and 
hematocrit values. Additionally, F1, together with F3, increased 
the frequencies of multifunctional CD3+CD8+ T cells, which were 
correlated with the increased spleen and liver sizes (Table 2). As 
an additional marker of the progression of the disease, F3 also 
induced an increase in the frequencies of CD3+CD8+IL-2+TNF-
α−IFN-γ+ T cells, which correlated with an increase in liver size. 
Conversely, as a marker of resistance, F2 increased the frequency 
of multifunctional cells, which was correlated with increased 
leukocyte and neutrophil counts. Furthermore, F2, together with 
NH36, enhanced proportions of CD3+CD8+IL-2−TNF-α+IFN-γ+ 
T cells which were correlated with the monocyte counts (Table 2).
Additionally, the cytokine responses of the CD4+ (Figure 2A) 
and CD8+ T cells (Figure 3A) induced by the SLA antigen were 
inferior, or did not differ from those promoted by NH36 and its 
domains.
Mapping of the cD4+ and cD8+ T cell 
epitopes
Aiming to map the epitopes responsible for the described T cell 
response against NH36 domains, we first compared the sequence 
of the gene of L. donovani NH36 to the sequence of the NH 
gene of the close related species L. infantum chagasi, which is 
the etiological agent of VL in Brazil (Figure 4A). While NH36 
of L. donovani is composed of 314 amino acids, the NH of L. 
infantum chagasi was described as containing 297 amino acids. 
The Blast analysis comparing the two sequences indicated 99% 
homology (Figure 4A). The difference between the two proteins 
is based on only one amino acid at position 192. The aspartate (D) 
residue of L. donovani NH36 is substituted with asparagine (N) in 
the Lch-NH sequence (Figure 4A). This result suggests that the 
recombinant domains of L. donovani NH36 could generate a suc-
cessful cross-protection against infection by L. infantum chagasi.
Additionally, confirming our experimental results, the 
TEPITOPE program, with a 3% threshold, identified one 
epitope for CD4 T cells in the F1 domain and two epitopes in 
the F2 domain of NH36 (Table  3). These three CD4 epitopes 
showed high percent of predicted binding to HLA-DR 
molecules (Table  3) and are highly promiscuous. In fact, 
the epitope “AAGCTKPLVRGVRNASQIHG” of F1 (64–93) 
binds to 20 among the 25 most frequent human HLA DR 
molecules (DRB1*0301, DRB1*0401, DRB1*0402, DRB1*0404, 
DRB1*0405, DRB1*0410, DRB1*0801, DRB1*0802, DRB1*0804, 
DRB1*0806, DRB1*1101, DRB1*1104, DRB1*1106, DRB1*1107, 
DRB1*1305, DRB1*1307, DRB1*1311, DRB1*1321, DRB1*1501, 
and DRB1*1502). The epitope “GRHAVQLIIDLIMSHEPKTI” of 
F2 (102–121) binds to 21 of the 25 most frequent human HLA DR 
molecules (DRB1*0102, DRB1*0301, DRB1*0401, DRB1*0402, 
DRB1*0404, DRB1*0405, DRB1* 410, DRB1*0421, DRB1*0801, 
DRB1*0802, DRB1*0804, DRB1*0806, DRB1*1101, DRB1*1104, 
DRB1*1106, DRB1*1107, DRB1*1305, DRB1*1311, DRB1*1321, 
DRB1*1501, and DRB1*1502). Additionally, the epitope 
“DRVKEVVLMGGGYHTGNASP” of F2 (144–163) binds to 19 
of the 25 most frequent human HLA DR molecules (DRB1*0101, 
DRB1*0102, DRB1*0404, DRB1*0405, DRB1*0410, DRB1*0801, 
DRB1*0802, DRB1*0804, DRB1*0806, DRB1*1101, DRB1*1104, 
DRB1*1106, DRB1*1107, DRB1*1307, DRB1*1311, DRB1*1321, 
DRB1*1501, DRB1*1502, and DRB5*0101) (Figures 4A,B).
Also supporting our experimental results, two and three CD8 
epitopes for the HLA class I molecules were predicted in the 
sequences of F1 and F3 domains, respectively (Table 3), by the 
SYFPEITHI software (Figures 4A,C), while no epitope for CD8 
was predicted in the sequence of F2.
The CD4 and CD8 epitopes (Figure 4A) are completely con-
served and have identical composition in the sequences of NH 
of L. donovani, L. infantum chagasi, and L. infantum (Tables 4 
and 5), which are the three species causing VL. Minor variations 
in 1–3 or 1 amino acids were detected in the CD4+ and CD8+ 
epitopes, respectively, of all other species, which also belong to 
the subgenus Leishmania. Additionally, variations in 3–5 and 1–4 
amino acids were observed in the sequences of CD4+ and CD8+ 
epitopes of Leishmania panamensis and L. braziliensis, which are 
species that belong to the genus Viannia (Tables 4 and 5). The 
FigUre 3 | continued
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FigUre 3 | continued 
Distinct quality of cD8 T cell response induced by nh36 or its domains. PBMCs were incubated in vitro with 10 μg/ml recombinant NH36, F1, F2, and F3 
antigens or with no antigenic stimulation for 6 h and further treated with brefeldin A for additional 12 h. Then the cells were stained for surface CD3 and CD8 
markers, fixed, permeabilized and stained for the intracellular expression of IL-2, TNF-α, and IFN-γ. Multiparametric flow cytometry was used to determine (a) the 
frequencies of CD3+CD8+ lymphocytes, and of CD3+CD8+ lymphocytes single producers of each one of the three cytokines (CD3+CD8+IL-2+TNF-α–IFN-γ–, 
CD3+CD8+IL-2–TNF-α+IFN-γ–, and CD3+CD8+IL-2–TNF-α–IFN-γ+), double producers (CD3+CD8+IL-2+TNF-α+IFN-γ–, CD3+CD8+IL-2–TNF-α+IFN-γ+, and CD3+CD8+IL-
2+TNF-α–IFN-γ+), and multifunctional CD8 T cells (CD3+CD8+IL-2+TNF-α+IFN-γ+); as well as the total frequencies of CD8 T cells producing IL-2 (CD3+CD8+IL2+) and 
(B) the fraction of the total CD3+CD8+ T cell response comprising cells expressing all three cytokines, any two cytokines, or any one cytokine in healthy individuals 
(control N = 10), active visceral leishmaniasis (VL) patients before therapy (BT N = 7), cured VL patients after therapy (AT N = 9), and in asymptomatic DTH+ 
individuals (DTH+ N = 10). The frequencies of each cytokine expressing phenotype were recorded after background subtraction of cells incubated without antigen. 
Results in panel (a) are expressed as means + SE. Asterisks and horizontal lines indicate significant differences from all other groups.
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presence of these highly conserved epitopes explain the high 
degree of cross-species recognition displayed by lymphocytes of 
patients infected with L. infantum chagasi against the L. donovani 
NH36 recombinant domains.
In order to confirm the accuracy of the in silico predictions, 
the CD4 predicted epitopes of F2 and F1 and the CD8 predicted 
epitopes of F1 and F3 domains were chemically synthetized and 
incubated in vitro with PBMC of asymptomatic DTH+ subjects. 
The secretion of IFN-γ to PBMC supernatants in response to 
those epitopes was assessed by an ELISA assay (Figure 5). The 
three predicted epitopes for CD4+ T cells promoted IFN-γ secre-
tion. The IFN-γ response generated by the epitope F2 (102–121) 
was 85% higher (mean = 5.35 pg/ml; P = 0.006) than that induced 
by the F2 epitope (144–163) (mean +  0.79  pg/ml), and 60% 
stronger (P = 0.050) than that induced by the F1 (64–93) epitope 
(mean = 2.14 pg/ml) (Figure 5). Levels of IFN-γ secreted after 
incubation with the F2 (102–121) epitope were not different from 
those obtained in response to the SLA complex antigen indicating 
that this is the major epitope responsible for the immunodomi-
nance of the F2 domain detected in all previous immunological 
assays. IFN-γ secretion was also directed against two predicted 
epitopes for the CD8 T cells of the F1 domain (sequences 20–28 
and 92–100), which were no different from SLA antigen, but not 
for the epitopes of the F3 domain (Figure 5).
DiscUssiOn
Patients of this study showed the typical clinical outcomes of VL 
(3, 4, 8, 40). On the other hand, no alterations were detected in 
cured or DTH+ individuals, whose PBMCs secreted the most 
pro-inflammatory cytokines, mainly in response to F2 and F1, 
and also secreted higher levels of TNF-α and IL-1β than those 
induced by the L. donovani lysate. The antigenic predominance of 
F2 is related to the finding of two predicted CD4 T cell epitopes 
in its sequence, while only one epitope is located in F1, and 
none is located in F3. Confirming these results, the additional 
increases in the secretion of IFN-γ and IL-17, in response to F2 
and F1 were highly correlated with the reduction of VL clinical 
signs, suggesting that F2 and F1 are indeed the NH36 markers 
of the Th1-mediated cure or resistance to VL (9). In agreement 
to those results, the epitopes (102–121 and 144–163) of F2 and 
the sequence (64–93) of F1 induced the highest IFN-γ responses 
in DTH+ individuals. Therefore, our immunological results sup-
ported the in silico predictions of epitopes for CD4+ T cells.
Epidemiological studies performed in Brazil (6, 41, 42) and 
Kenya (43) have shown that a positive DTH response is a marker 
for developing acquired resistance to human VL (5, 41, 43). In the 
north east of Brazil, where the present study was also developed, 
the DTH+ response was proved to be under genetic control (6, 42, 
43) with some genotypes associated to DTH+ subjects and other 
to DTH− subjects (42). A DTH positive phenotype is considered 
not only a measure of acquired resistance to natural infection (41, 
43), but also, the only correlate with date of protection in human 
vaccine trials (44–46). Our results are thus relevant considering 
that we described the conserved domains and epitopes of L. 
donovani, L. infantum, and Lch-NHs that promote Th1 responses 
in DTH+ subjects and, because of that, which correlate with the 
resistance to L. infantum chagasi infection.
While the hallmark of VL is associated with an impairment of 
Th1 responses and a depressed cell-mediated immune response 
characterized by the failure of PBMCs of untreated patients to 
produce IFN-γ in response to leishmanial antigens (47–49), in 
our study, the F2 peptide alone promoted the highest secretion 
of IFN-γ, IL-1β, and TNF-α in cured and DTH+ subjects. In 
fact, the IFN-γ and TNF-α levels produced by DTH+ subjects 
in response to F2 are two or three orders of magnitude higher, 
respectively, than those detected in cured patients from India in 
response to SLA, and one order of magnitude higher than those 
obtained in response to the antigens LACK and TRYP (4). Also, 
similar to our results, cured patients of India produce IFN-γ and 
TNF-α in response to antigens (48, 49) providing correlates of 
resistance (4). Additionally, Th1 responses including a robust 
TNF-α response directed against NH36 were also recently 
described in human healthy subjects vaccinated with an NH36-
fusion protein (11). The pro-inflammatory enhanced cytokine 
secretion in response to F2 and F1 domains indicated that they 
are the targets of the anti-NH36 immune response related to VL 
resistance.
We therefore revealed in our study the main domains and 
epitopes of NH36 which can be considered as potential candidates 
for a T-epitope vaccine for humans. Indeed, while prediction pro-
grams and pre-clinical studies in mice indicated the importance of 
three CD4 epitopes of F3, and two of F1 (26) in the generation of 
protection against visceral and CL, our study conversely describes 
two CD4 epitopes for humans in the F2 and one in F1. Therefore, 
the F2 domain, which is not relevant for mouse immunity (12, 13, 
26), is however responsible for the generation of the strongest Th1 
responses in humans.
TaBle 3 | Peptide sequences of the nh36 antigen selected by the TePiTOPe and sYFPeiThi algorithms.
amino acid location lymphocytes Domain sequences Prediction of molecular binding
hla-Dr (%)a hla-a and B scoresb
64–93 CD4 F1 AAGCTKPLVRGVRNASQIHG 80 –
102–121 CD4 F2 GRHAVQLIIDLIMSHEPKTI 84 –
144–163 CD4 F2 DRVKEVVLMGGGYHTGNASP 76 –
20–28 CD8 F1 FLAHGNPEV – 28 (A*02:01)
92–100 CD8 F1 YPPEFKTKL – 21 (B*0702)
197–205 CD8 F3 ALATPAVQK – 34 (A*03)
211–219 CD8 F3 AFMLQILDF – 19 (B*4402) 17 (A*2402)
221–229 CD8 F3 ILDFYTKVY – 27 (A*01)
aPredictions were calculated using the TEPITOPE algorithm using 3% threshold.
bPredictions obtained using the SYFPEITHI algorithm.
FigUre 4 | spatial distribution of epitopes in the monomer of the Leishmania donovani nucleoside hydrolase nh36 (ld-nh36) and homology to the 
sequence of Leishmania infantum chagasi nh (lch-nh). (a) Blast of the sequences of Ld-NH36 and Lch-NH with the sequences of the predicted epitopes for 
HLA class II molecules identified with a 3% threshold by the TEPITOPE program shown in blue boxes and the epitopes for HLA class I molecules identified by the 
SYFPEITHI software shown in red boxes. (B) The NH36 monomer model obtained by homology modeling to the sequence of the nucleoside hydrolase of 
Leishmania major. The model shows the N-terminus (F1, amino acids 1–103) in lime green, the central domain (F2, amino acids 104–198) in gray, and the 
C-terminus (F3, amino acids 199–314) in cyan. The CD4+ T-cell epitopes are plotted in dark blue, and (c) the sequences of the CD8+ T-cell epitopes are  
labeled in red.
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IL-1β, which is highly induced by F2, is a pro-inflammatory 
cytokine secreted by monocytes and macrophages, which pro-
motes inflammatory responses that activate protective immunity. 
In agreement to that, the increase in IL-1β secretion of cured and 
DTH+ subjects of the same endemic area, was associated with 
the decrease of the parasite load of infected macrophages (50). 
Furthermore, host resistance to infections by L. major (24), L. 
amazonensis, L. braziliensis, and L. infantum chagasi, which share 
a high degree of identity in their NH sequences (13, 31), has also 
been described to be mediated by IL-1β (51). Thus, the IL-1β 
FigUre 5 | iFn-γ secretion induced by the synthetic predicted 
epitopes of nh36. PBMCs of asymptomatic subjects (N = 6) were 
incubated in vitro with 10 μg/ml of the synthetic predicted epitopes of NH36 
or with Leishmania donovani stationary phase lysate, or with no addition, for 
72 h. IFN-γ secretion in supernatants was measured with Invitrogen NOVAK 
Magnetic Beads Assay. Asterisks and horizontal lines indicate significant 
differences between groups. The means + SE are shown.
TaBle 5 | conserved epitopes for cD8+ T cells of the genus Leishmania.
Leishmania species cD8-F1 (20–28) cD8-F1 (92–100) cD8-F3 (197–205) cD8-F3 (216–224) cD8-F3 (221–229)
L. donovani FLAHGNPEV YPPEFKTKL ALATPAVQK AFMLQILDF ILDFYTKVY
L. infantum chagasi FLAHGNPEV YPPEFKTKL ALATPAVQK AFMLQILDF ILDFYTKVY
L. infantum FLAHGNPEV YPPEFKTKL ALATPAVQK AFMLQILDF ILDFYTKVY
L. amazonensis FLAYGNPEI YPPEFKTKL ALATPAVRK AFMLGILDF ILDFYTKVY
L. major FLAHGNPEI YPPEFKTKL ALATPAVQK AFMLQILDF ILDFYTKVY
L. tropica FLAHGNPEI YPPEFKTNL ALATPEVQK AFMLQILDF ILDFYTKVY
L. mexicana F LAYGNPEI YPPEFKTKL ALATPAVRK AFMLGILDF ILDFYTKVY
L. braziliensis LLAYGNPEI YPSEFKTKL ALATPEVLQ DFILKILEF ILEFYTKVY
L. panamensis LLAYGNPEI YPSEFKTKL ALATPEVLQ DFILKILEF ILEFYTEVY
The amino acids that are different from those of the sequence described in the Nucleoside hydrolase NH36 of L. donovani.
TaBle 4 | conserved epitopes for cD4+ T cells within the genus Leishmania.
Leishmania species epitope cD4-F1 (64–93) epitope cD4-F2 (102–121) epitope cD4-F2 (144–163)
L. donovani AAGCTKPLVRGVRNASQIHG GRHAVQLIIDLIMSHEPKTI DRVKEVVLMGGGYHTGNASP
L. infantum chagasi AAGCTKPLVRGVRNASQIHG GRHAVQLIIDLIMSHEPKTI DRVKEVVLMGGGYHTGNASP
L. infantum AAGCTKPLVRGVRNASQIHG GRHAVQLIIDLIMSHEPKTI DRVKEVVLMGGGYHTGNASP
L. amazonensis AAGCAKPLVRGVRNASQIHG SRHAVQLIIDLIMSHEPKTI ERVKKVVLMGGGYHTANASP
L. major AAGCTKPLVRGVRNASIHIG GRHAVQLIIDLIMSHEPKTI DRVKEVVLMGGGYHTGNASP
L. tropica AAGCTKPLVRGVRNASQIHG GRHAVQLIIDLIMSHEPKTI DRVKEVVLMGGGYHTGNASP
L. mexicana AAGCAKPLVRGVRNASQIHG SRHAVQVIIDLIMSHEPKTI ERVKEVVLMGGGYHTANASP 
L. braziliensis AAGCCKPLVRKVRTAPQIHG KRHAVHLIIELIMSHEPKSI ERVKEVVLMGGSCCIGNASP
L. panamensis AAGCCKPLVRKVRTAPQIHG KRHAVHLIIELIMSHEPKSI ERVKEVVLMGGSCCIGNASP
The amino acids that are different from those of the sequence described in the Nucleoside hydrolase NH36 of L. donovani.
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secretion induced by the F2 domain could contribute to the basis 
of this cross-species resistance induced by NH36.
IL-12 secretion by VL untreated patients was higher in 
response to F2 than to SLA. As in our study, similar or higher 
levels of IL-12 were detected in the sera of infected untreated 
patients and subclinical DTH+ subjects from Bangladesh (52) and 
Brazil (53). IL-12 is associated with macrophage activation, para-
site phagocytosis, and a protective host response that upregulates 
IFN-γ synthesis, cytolytic activity, and Th1 cell differentiation (3). 
Therefore, the finding of increased levels of IL-12p70 in untreated 
patients in response to F2 might indicate its involvement in the 
generation of an early inflammatory response as an attempt to 
control infection (53, 54).
Enlarged spleen and livers and decreased hemoglobin, albu-
min, and hematocrit counts correlate with the clinical variables 
(55–58) and the increased blood parasite load found in VL (55). 
By contrast, in our study, the increase of both IL-17 and IL-6 
secretion in response to F1 and F2 correlated with decreases in 
spleen and liver sizes, which are parameters of cure and asymp-
tomatic VL (56, 58).
The increased secretion of IL-17 in response to F1 also cor-
related with an increase in monocytes as well as with an increase 
hemoglobin counts. IL-17 is a classical effector of innate immunity 
that induces the expression of many inflammatory mediators, 
including IL-6 (8). Our results then indicate the efficient induc-
tion of a Th17 response by the F2 and F1 domains that contributes 
in the cure and control of the infection.
Besides inducing Th1 and Th17 responses, the F2 and F1 
domains also promoted the secretion of IL-10, a cytokine which 
was correlated with immunosuppression defects (8, 59) and, 
together with IL-6, with the severity of human VL (60). This 
kind of mixed Th1/Th2 response was also previously described 
for VL (49). In fact, in our study, IFN-γ, IL-17, and IL-10 were 
co-expressed by PBMCs of healthy, cured, and DTH+ subjects 
and their secretion was lower in untreated patients. Since 
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DTH+ is a marker of acquired resistance to VL (5, 42, 43), the 
increased IL-10 secretion in response to NH36 domains, in 
cured and DTH+ subjects is more associated with resistance 
and cure of VL than with a Th2 response. As we described here 
for the NH36 domains, another Leishmania vaccine candidate, 
the LaPSA-38S antigen induced specific Th1 responses and 
protection in mice and promoted significant levels of IFN-γ, 
granzyme B, and IL-10 in patients cured from cutaneous L. 
major infection and in high responders asymptomatic subjects 
infected with L. major or L. infantum (61). A higher secretion 
of TNF-α in response to LaPSA-38S was also found in the L. 
infantum high responders (61). As described for LaPSA-38S 
protein, the NH36 domains were able to induce a mixed Th1 
and Th2/Treg cytokine response in individuals with immunity 
to L. infantum chagasi indicating that it may be exploited as a 
vaccine candidate. The IL-10 elevated secretion in response to 
NH36 domains might be determined by the increased secretion 
of TNF-α (60, 62) and might serve as a tool for control of tissue 
damage caused by the enhanced inflammatory response. The 
increased secretion of IL-10 in response to NH36 also suggests 
the presence of Treg epitopes in its domains. Confirming that, 
it was described that the parasite-induced IFN-γ and IL-1β act 
on DCs and macrophages to promote the production of IL-27, 
which blocks the generation of Th17 cells and facilitates the 
generation of IL-10-producing T cells (8). Remarkably, this 
ability of modulating the immune response, and promoting 
similar levels of IFN-γ, TNF-α, and IL-10 associated to resist-
ance was also found after human vaccination with an NH36-
fusion protein (11), in DTH+ asymptomatic CL patients (63), 
in L. infantum-infected asymptomatic dogs (64), and in mice 
vaccinated with F1 (26). Therefore, our results suggest that a 
combination of CD4 Th1 and/or potential regulatory epitopes 
of F2 and F1 modulate the human immune response against 
the parasite. This seems to be also the case for IL-6, which is 
produced by APCs and involved in the control of Th1/Th2 dif-
ferentiation during CD4 T cell activation and is found in the 
plasma of VL patients and asymptomatic subjects in Brazil (65). 
The F2 and F1 domains could be therefore the basis of tools for 
prevention, control, or new methods of immunotherapy of this 
severe potentially lethal disease.
Optimal vaccine protection is achieved by developing a 
population of multifunctional IL-2+TNF-α+IFN-γ+ producing 
CD4 T cells that can mediate effector functions quickly, and 
by having a memory T-cell reservoir that secretes IL-2, TNF-
α, or both and shows effector potential (66). Consistent with 
this, F2 induced the most robust cytokine responses and the 
highest frequencies of CD3+CD4+IL-2+TNF-α+IFN-γ+ effector 
T cells, CD3+CD4+IL-2+TNF-α−IFN-γ−, and CD3+CD4+IL-
2+TNF-α+IFN-γ− T cells in asymptomatic individuals. F2 also 
most efficiently promoted the expression of IL-2 and TNF-α by 
CD4+ T cells and promoted the development of multifunctional 
T cells in cured patients, followed by F1 in DTH+ subjects. 
The correlations observed between the increases in propor-
tions of multifunctional, CD3+CD4+IL-2-TNF-α+IFN-γ−, and 
CD3+CD4+IL-2−TNF-α−IFN-γ+ T cells and leukocytes, 
neutrophils, and monocytes induced by F1 also confirm that, 
for some variables, F1 is co-dominant with F2. The increased 
IFN-γ secretion of PBMC of asymptomatic subjects in response 
to the predicted CD4+ epitopes of F2 (102–121 and 144–163) 
and F1 (69–93) explains those results. Confirming the relevance 
of NH36 in cross-species protection, enhanced frequencies of 
anti-NH36 IL-2, TNF-α, or IFN-γ-producing CD4+ T cells, 
indicating the generation of a memory-response, have also been 
reported, in asymptomatic patients of Bangladesh (11) and in 
mice vaccinated after L. amazonensis infection (12, 13, 25, 26).
Unlike CD4 lymphocytes, following antigenic stimulation, 
naïve CD8 T cells differentiate into activated effector cells that 
can transform into CD8+IL2−TNF-α+IFN-γ+ effector cells or 
into multifunctional CD8+IL2+TNF-α+IFN-γ+ memory cells 
(66). We described that the CD8+ T cells response against F1 and 
F3 is related to the advancement of the disease as most of the 
CD8+ phenotypes are increased in untreated patients. However, 
positive correlations were found between the increases in 
CD3+CD8+IL2+TNF-α−IFN-γ−, CD3+CD8+IL2+TNF-α+IFN-γ+, 
and CD3+CD8+IL2+TNF-α−IFN-γ+ T cell frequencies and the 
increases in spleen and liver sizes. These positive correlations 
indicate that, in these untreated patients, the CD8+ T cells could 
be involved in an early attempt to control the parasite loads of 
liver and spleens. Supporting the multiparameter analysis two 
synthetic predicted CD8+ epitopes of the F1 domain induced the 
IFN-γ secretion by PBMC of DTH+ subjects.
In agreement to our results, in CL models, CD8 T cells produc-
ing IFN-γ were considered as very important for directing Th2-
type responses toward Th1 (67) and for establishing long-term 
memory that protects against re-infections (68). Memory CD8 
T cells have been shown to be responsible for resistance against 
re-infection (69) and for promoting long-lasting protection, 
which is lost in their absence (70, 71). This evidence could also 
explain our finding of high percentages of CD3+CD8+IL-2−TNF-
α−IFN-γ+ single positive cells observed in the DTH+ group, which 
represent the immune resistance to VL, after stimulation with F1 
and F3 domains.
We further described the prediction of two promiscuous 
epitopes for CD4+ lymphocytes in the F2, and one in the F1 
domain, which are all capable of binding to at least 19 of the 
25 most frequent human HLA-DR molecules. These predic-
tions were confirmed by the ability of F2 and F1 domains to 
induce CD4 Th1 responses, and the competence of the respec-
tive synthetic predicted epitopes, mainly the F2 (102–121) 
followed by the F1 (64–93), to promote the IFN-γ secretion 
by PBMC of DTH+ subjects. These results are very impressive 
considering that HLA class II prediction is more difficult and less 
reliable (14).
In this investigation, we demonstrated that F2 and F1 domains 
induce a strong CD4+-Th1 response in cured and DTH+ sub-
jects, whereas the F1 and F3 domains promote a higher CD8+ 
T cell pro-inflammatory response in untreated patients and an 
increase in the CD3+CD8+IL-2−TNF-α−IFN-γ+ T cell propor-
tions in DTH+ subjects. Both CD4 and CD8 responses can be 
related to the control and resistance to L. infantum chagasi 
infection.
Our objective in this study was to determine which are the 
more immunogenic domains of NH36. This would allow us to 
confirm the relevance of the epitopes disclosed by the in  silico 
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prediction programs and to define a rationale combination of the 
domains and/or epitopes to be used in a future universal vaccine 
against leishmaniasis, capable of enhancing both arms of T-cell 
immunity.
The epitopes were indeed identified by the prediction programs 
directly, on the sequence of the whole NH36 molecule, both for 
mice (26, 28) and human histocompatibility complex molecules 
(this manuscript). However, although the identification of the 
epitopes would allow the direct design of a synthetic epitope vac-
cine, it has been reported that the results of the immunological 
assays in vivo not always confirm the in silico predictions (32), and 
that the synthetic epitopes alone are not enough immunogenic 
to be used as vaccine candidate antigens (14). Our strategy then 
was to identify through immunological assays the presence of 
the important epitopes in the domains of the NH36 antigen that 
would therefore be more immunogenic than the whole cognate 
NH36 protein and more potent than the isolated epitopes, when 
used in vaccination.
The reason for evaluating the individual domains of the same 
antigen in order to identify the epitopes is that the domains, 
which contain potent epitopes, will be more potent than the whole 
antigen. This will indeed allow the selection of the truly relevant 
epitopes among all epitopes disclosed by the in  silico software. 
The immunogenic domains in fact concentrate the immunogenic 
power of the whole antigen. Hence, for instance, if we use for 
incubation with PBMC one molecule of NH36, among its 314 
amino acids, 40 of them compose the sequences of the three 
epitopes for CD4 located in F3. This means that one molecule of 
NH36 has 12.7% (40/314) of its sequence constituted by epitopes 
for CD4 T cells. If by contrast, we vaccinate only with a molecule 
of F3, which is composed by 115 amino acids, the 40 amino acids 
of the CD4 epitopes would represent now 34.8% (40/115) of 
the antigen, and this is what induce a threefold increase in the 
immunogenic effect. We are, in this way, exposing PBMC to a 
higher molar concentration of the relevant epitopes. That is why 
more protection is expected to be generated by the domain that 
contains the epitopes than by the whole NH36. A higher molar 
concentration of the epitopes is expected to be found in it than in 
the whole cognate protein.
In agreement with this idea, the F3 vaccine promoted in mice 
a 36% higher average protection than the NH36 vaccine. This 
average increased protection induced by the F3 vaccine above the 
level promoted by the NH36 vaccine included: a 32.06% higher 
IDR, 24  h after immunization, a 34.1% higher IDR 48  h after 
immunization, a 21.4% higher IDR 48 h after challenge, a 37.39% 
enhanced IFN-γ/IL-10 CD4+ T cell ratios, a 27. 18% stronger 
reduction of parasite load by in  vivo depletion with anti-CD4 
monoclonal antibody, a 57.99% increment in reduction of the 
parasite load of L. chagasi, and a 47% reduction in parasite load 
by L. amazonensis (26). That means that while the NH36 vaccine 
reduces the L. chagasi parasite load in 37%, the F3 reduces it in 
88% (26).
Additionally, the F3 vaccine was 40% average more protec-
tive than the NH36 vaccine against L. amazonensis infection 
(28). This included a 27.58% stronger IDR, 48 h after challenge, 
a 20.04 and 11.64% enhanced secretion of IFN-γ and TNF-α to 
supernatants, respectively, and a 93.03% reduced L. amazonensis 
parasite load (28). The calculation was performed according the 
following equation = (F3 − NH36/F3) values × 100 and allowed 
us to obtain the protective effect increment (26).
Noteworthy, for mice, the prediction software had disclosed 
two epitopes for CD4 in F1, one in F2, and three in F3. On the 
other hand, one epitope for CD8 T cells was disclosed in F1 and 
two in F2 (26). The immunological in vivo assays, on the other 
hand, only confirmed the relevance of the three epitopes for CD4 
of F3 and of the single epitope for CD8 T cells of F1 (26, 28, 29). 
Therefore, the immunological assays only partially confirmed the 
in silico prediction for the mice model (32). No response against 
the F2 domain was observed in vaccinated mice. In fact, the F3 
domain induced the strongest CD4-mediated protection against 
VL infection (26) and, besides F3, the F1 domain induced an 
additional CD8-mediated response against L. amazonensis infec-
tion (26, 28).
Therefore, if the domains, which contain the important 
epitopes, are more potent than the whole protein, the need of 
evaluation the individual domains in order to confirm the 
epitopes is justified. In order to increase potency and optimize 
a vaccine, for instance, the domains could be even combined in 
a chimera that would be expected to be even more potent than 
the single domains. Our results support those of Kao et al. for the 
Pseudomonas aeruginosa Type IV pilus vaccine (72). The authors 
compared antisera raised against the PAK strain monomeric 
pilin protein (29−144) and a synthetic peptide containing the 
main receptor-binding domains (RBDs) of the pylus (128−144). 
They showed that not only does the synthetic peptide generated 
higher titers of RBD-specific antibodies but that the anti-peptide 
antibodies have a higher affinity for the native protein than the 
anti-pilin (72). The strategy of using the domains that concentrate 
the most relevant epitopes was the basis of the development of 
the development of the vaccines against human malaria (central 
and C-terminal domain) (73), HIV (CD4 and co-receptor bind-
ing domains) (74), and influenza [extracellular domain of matrix 
protein 2 (M2e)] (75).
In this investigation, we are not analyzing vaccinated indi-
viduals that have a strong response to the correct epitopes. We 
are studying instead human VL cured and DTH+ subjects, trying 
to detect to what portion of the NH36 molecule the acquired 
resistance and immunity of these patients is directed. These 
individuals, although representing the Th1 pole of the immune 
response to VL, and being expected to have the strongest natu-
rally acquired immune resistance to VL (41–43), display milder 
immune responses, in in vitro assays, if compared to vaccinated 
subjects. Therefore, the search for immunogenicity is more 
difficult, and small signals of increase of the immune reactivity 
should be considered in order to map the best immunogenic 
domain.
It is worth to note that the predicted epitopes are different in 
mice and in human histocompatibility complexes. For humans the 
in silico programs disclosed two epitopes for CD3+CD4+ T cells 
in F2 and one in F1, and further three epitopes for CD3+CD8+ T 
cells in F1 and additional three in F3. In agreement to that, we 
were able to show that the most pronounced CD4-Th1 response 
was directed against F2 and F1 domains, and the strongest CD8+ 
response target the F1 and F3 proteins.
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In fact, the F2 induced 76% higher frequencies of CD3+CD4+IL-
2+TNF-α+IFN-γ− than F1, in DTH+ subjects, and 100% higher 
proportions of multifunctional IL-2+TNF-α+IFN-γ+ T cells than 
F1 and F3, respectively, in cured patients. Additionally, in DTH+ 
individuals, F2 increased the CD3+CD4+IL-2+TNF-α−IFN-γ− T 
cell frequencies 67% more than F1 and 69% more than F3. F2 
also enhanced the CD3+CD4+IL-2+ T cell proportions 72% more 
than F1 and 70% more than F3. Furthermore, F2 was 59 and 87% 
stronger than F1 and F3 domains, respectively, but most impor-
tant, it was 96% more potent than NH36, in the enhancement of 
the frequencies of CD3+CD4+IL-2+TNF-α−IFN-γ+ T cells of the 
DTH+ subjects.
Accordingly, F2 was the only domain that retained the capa-
bilities of NH36 to enhance the IFN-γ secretion. Additionally, F2 
increased the TNF-α secretion 10% more than NH36, and 28% 
more than the very potent SLA, in cured subjects.
Similar to our results of multiparameter analysis, the increased 
IFN-γ secretion by PBMC of DTH+ subjects, in response to the 
synthetic epitopes predicted for CD4+ T cells disclosed, the F2 
(102–121) epitope which promoted a 86 and 60% higher secre-
tion of IFN-γ than the sequences F2 (144–163) and F1 (64–94), 
respectively.
Regarding the induction of the CD8+ T cell response, the 
reactivity was higher in untreated patients. F1 and F3 increased 
the frequencies of CD3+CD8+IL-2+TNF-α−IFN-γ− T cells above 
the levels of NH36, by 90 and 89%, respectively. Also, F1 was 59% 
and F3, 78% more potent than NH36 in the enhancement of the 
frequencies of CD3+CD8+IL-2+ T cells. F3 was additionally 77% 
stronger than NH36, in the increase of the CD3+CD8+IL-2+TNF-
α−IFN-γ+ T cell frequencies. Finally, F1 was 99% and F3, 100% 
stronger than NH36, in the enhancement of the multifunctional 
CD3+CD8+IL-2+TNF-α+IFN-γ+ T cell proportions.
Accordingly, the two synthetic predicted epitopes for CD8 T 
cells of the F1 domain, F1 (20–28) and F1 (92–100), promoted the 
secretion of IFN-γ of PBMC of DTH+ subjects. The F3 epitopes 
however did not. This is possible due to the fact that the PBMC 
incubated with the synthetic epitopes belonged to DTH+ subjects 
and not to untreated patients. The analysis should be extended to 
untreated patients in order to give more information.
We conclude that, in this investigation, the information 
disclosed by the immunological assays with the domains was 
mostly supported by the in silico predictions. The use of the single 
immunogenic domains also induced protective effect increments 
above those promoted by NH36 and/or the other domains. These 
results will allow us to guide the initiation of the development of 
a synthetic vaccine against leishmaniasis.
The importance of our findings is enhanced considering three 
rare achievements (76): (1) we found CD4 Th1-cell epitopes of 
a CD4 T cell mediated immunosupressive disease; (2) they are 
highly promiscuous and bind to many HL-DR allotypes; and (3) 
they are extremely conserved and present in Leishmania of two 
subgenera that cause visceral, cutaneous, diffuse, and mucocuta-
noeus leishmaniasis.
Previously, all of the vaccine approaches against leishmania-
sis have focused on the stimulation of the CD4 T cell response 
and have neglected the important contribution of CD8 T cells 
(14). However defined epitopes for both CD4 (LACK) (77) 
and CD8 (KMP11; GP63, CPB, CPA, Lpg2, histone 3 variant, 
histone H4)-mediated protective responses against Leishmania 
(78, 79) were described. Recently, it has been proposed that 
vaccine design will improve through the search for potential 
candidates that share both CD4- and CD8 T-cell-stimulating 
capabilities (NH36, A2, P4) (8, 12–14, 26, 80) and through 
their expression as polytope or poly-epitope vaccines (14, 81). 
Recently published data indicate that CD8 T cells are very 
important in protection against L. major infection induced 
by a polytope DNA construct expressing individual MHC-
I-restricted peptides in BALB/c mice (82). In that study, the 
vaccine stimulation of CD8 T-cells resulted in partial protection 
which was abolished by CD8 T-cell depletion resulting in a 
predominant Th2 response. This directly confirmed the role of 
CD8 T-cells in early-stage Th1 response polarization (82). We 
also previously described that the protection of mice against 
L. amazonensis infection induced by F1 was mediated by CD8 
T cells and was abolished by CD8 T cell depletion (12). The 
present investigation represents a step forward in the definition 
of the epitopes for CD8 T cells involved in IFN-γ secretion by 
human PBMC.
Our results confirm the relevance of NH36 in immune regula-
tion in human VL and identified its immunodominant domains 
and epitopes that could guide the design of a rational and cross-
protective T-cell vaccine against human leishmaniasis.
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